



Date: February 08, 2025

BSE Limited

Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai – 400 001 India

National Stock Exchange of India Limited

Exchange Plaza, C-1, Block G,
Bandra Kurla Complex,
Bandra (E), Mumbai – 400 051 India

Scrip Code: 543529

Symbol: DELHIVERY

Sub: Regulation 30 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 – Clarification in the disclosure related to appointment of Ms. Namita Thapar as an Independent Director of the Company.

Dear Sir/ Madam,

This is in continuation to the press release and disclosure under Regulation 30 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“**SEBI Listing Regulations**”) submitted on February 7, 2025, in relation to appointment of Ms. Namita Thapar (DIN: 05318899) as an Additional Director under the category of Independent Director of the Company.

In this regard, we wish to clarify that inadvertently in her brief profile, it was mentioned that she is the Executive Director and CEO of India Business of Emcure Pharmaceuticals Limited. Please note that she is the Whole-time Director of Emcure Pharmaceuticals Limited and heading its India Business.

Except for the above error and referred change, there is no other change in the aforesaid submissions to stock exchanges.

The aforesaid disclosure will also be hosted on the Company’s website at www.delhivery.com.

You are requested to take the above on records.

Thank you.

Yours sincerely,

For Delhivery Limited

Madhulika Rawat

Company Secretary & Compliance Officer

Membership No: F 8765